Board of Directors
Guiding the growth of Endocyte
John C. Aplin, PhD
Dr. John C. Aplin has served as a member of our Board of Directors since 2003 and was recently appointed as chairman. Since 1990, Dr. Aplin has served as general partner and managing director of CID Capital, a venture capital firm he joined after previously serving as president and chief executive officer of the Fuller Brush Company, a supplier of consumer products. Dr. Aplin holds a BS in business administration from Drake University, a MA in industrial and labor relations and a PhD in business administration from the University of Iowa. Dr. Aplin is also a certified management consultant.
Keith E. Brauer
Former VP Finance/Chief Financial Officer
Keith E. Brauer has served as a member of our Board of Directors since 2006. From 1974 to 1994, Mr. Brauer served in various executive roles at Eli Lilly and Company, a healthcare company, and most recently as executive director and chief accounting officer. From 1994 to 2006, Mr. Brauer served as vice president, finance, and chief financial officer of Guidant, which was acquired by Boston Scientific Corporation, a medical device company. Mr. Brauer holds a BS in management from Indiana University and an MBA from the University of Michigan.
P. Ron Ellis
Chief Executive Officer/President
P. Ron Ellis is one of our founders and has served as our president and chief executive officer since 1996 and as a member of our Board of Directors since 1995. Prior to joining Endocyte, Mr. Ellis was with Hill-Rom Company, the $1.2 billion healthcare division of Hillenbrand Industries. While at Hill-Rom, he held a variety of senior management positions, including vice president of strategy/corporate development and vice president of the specialty care division. Mr. Ellis holds a BS in computer science and an MBA from Brigham Young University, and a certification in regulatory affairs from Purdue University.
Colin Goddard, PhD
Chairman and Chief Executive Officer
Dr. Goddard joined our Board of Directors in 2013 and joined Coferon as an investor and executive chairman in 2011, assuming the CEO role following the Series B financing in 2012. From 1998 until its $4 billion acquisition by Astellas Pharma US, Inc. in 2010, Dr. Goddard was CEO of OSI Pharmaceuticals, Inc., a company he joined as a scientist in 1989. Dr. Goddard holds a BS in biochemistry from the University of York in York, United Kingdom, and a PhD in cancer pharmacology from Aston University in Birmingham, United Kingdom. Dr. Goddard serves on the boards of several public and private biotechnology companies and has been active in many organizations that promote the advancement of cancer treatment and awareness, science education, and the biotechnology industry.
Ann F. Hanham, PhD
BAR Capital Management
Dr. Ann Hanham has served as a member of our Board of Directors since 2004. Dr. Hanham is a Managing Partner with BAR Capital Management and has spent over 30 years in clinical and regulatory affairs working both in the federal government and biotech industry. Dr. Hanham has served on the board of directors of a number of private companies as well as Acusphere (OTCMKTS:ACUS), BioMimetic Therapeutics (NASDAQ:BMTI), Biotie Therapies (Nordic List:BTH1V), SCYNEXIS (NASDAQ:SCYX), and Targacept (NASDAQ:TRGT). Dr. Hanham holds a PhD from the University of British Columbia and was board certified in toxicology in 1986.
Mr. Kozin joined Endocyte’s Board of Directors in 2012 and is currently a senior advisor to L.E.K. Consulting, a global strategy consulting firm. Having served as president of L.E.K.’s North American practice for 15 years, Mr. Kozin has nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. He also has deep industry expertise advising biopharmaceutical, life sciences, and medical technology companies. Mr. Kozin also serves on the boards of UFP Technologies, Medical Simulation Corporation, CrunchTime! Information Systems, and DukeEngage. Mr. Kozin received his BA with distinction, Magna Cum Laude, in economics from Duke University. He was also awarded an MBA with distinction from The Wharton School, University of Pennsylvania.
Philip S. Low, PhD
Chief Science Officer
Dr. Philip S. Low is one of our founders and has served as our chief science officer since 1998 and as a member of our Board of Directors since 1995. Dr. Low has served on the faculty at Purdue University since August 1976, where he is currently the Ralph C. Corley Distinguished Professor of Chemistry. He holds a BS in chemistry from Brigham Young University and a PhD in biochemistry from the University of California, San Diego.
Peter D. Meldrum, PhD
President & Chief Executive Officer
Myriad Genetics, Inc.
Dr. Meldrum is currently the president and chief executive officer of Myriad Genetics, a position he has held since 1992. Prior to his time at Myriad, he was president and chief executive officer of Founders Fund, Inc., a venture capital group investing in the biotechnology industry, and has been active in the biotechnology industry for over 35 years. Dr. Meldrum received a BS in chemical engineering, an MBA, and a PhD in engineering (honorary) from the University of Utah, and a PhD in science (honorary) from Westminster College.
Fred A. Middleton
Sanderling Venture Partners
Fred A. Middleton has served as a member of our board of directors since July 2001. Since 1987, Mr. Middleton has been a general partner and managing director of Sanderling Ventures, a biomedical venture capital firm. During the last 30 years, Mr. Middleton has served in a number of management roles and as a member of the board of directors for over 20 biomedical companies. Mr. Middleton currently serves as a director of Stereotaxis, a medical device company, and until recently as the Chairman of the Board of Pacira Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Middleton also serves on the board of directors of five other privately-held biomedical and biotechnology companies. From 1978 through 1984, he served as Vice president and Chief Financial Officer for Genentech, Inc. Mr. Middleton holds a BS in chemistry from the Massachusetts Institute of Technology and an MBA with distinction from Harvard Business School.
Lesley Russell, MBChB, MRCP
Chief Operating Officer
Dr. Russell joined the Endocyte Board of Directors in 2012 and is currently the chief operating officer of TetraLogic Pharmaceuticals. Prior to TetraLogic, Dr. Russell served as senior vice president and head of research and development for global branded products at Teva Pharmaceuticals. She was appointed to this role upon Teva’s acquisition of Cephalon, Inc., where she served as executive vice president and chief medical officer. Dr. Russell joined Cephalon in 2000 and held various positions of increasing responsibility, including head of clinical research and medical affairs, prior to becoming Cephalon’s chief medical officer in 2006. During her tenure at Cephalon, Dr. Russell filed multiple NDAs to the FDA and marketing authorization applications (MAAs) to the Committee for Medicinal Products for Human Use (CHMP). Before joining Cephalon, Dr. Russell held positions at Amgen, UK, Lilly Industries, UK, and US Bioscience, now acquired by MedImmune Oncology. Dr. Russell received an MBChB degree from the University of Edinburgh, Scotland. She is a member of the Royal College of Physicians, UK, and is registered with the General Medical Council, UK. She currently serves as a member of the board of directors of AMAG Pharmaceuticals, a company traded on NASDAQ.